Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study).

A, Makiyama; Y, Sukawa; T, Kashiwada; J, Kawada; A, Hosokawa; Y, Horie; A, Tsuji; T, Moriwaki; H, Tanioka; K, Shinozaki; K, Uchino; H, Yasui; H, Tsukuda; K, Nishikawa; H, Ishida; T, Yamanaka; K, Yamazaki; S, Hironaka; T, Esaki; N, Boku; I, Hyodo; K, Muro

doi:10.1200/jco.19.03077

Public

Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study).

Shared by NobleBlocks on Mar 24, 2020 • 12:00 AM UTC

Authors:

Makiyama A

Sukawa Y

Kashiwada T

Abstract

Purpose This study evaluated the continuous use of trastuzumab beyond progression (TBP) in human epidermal growth factor receptor 2 (HER2)-positive advanced gastric or gastroesophageal junction (G/GEJ) cancer.Patients and methods Patients with HER2-positive advanced G/GEJ cancer refractory to first-...

Discussions